Bupivacaine-fentanyl elective group — Competitive Intelligence Brief

Bupivacaine-fentanyl elective group (Bupivacaine-fentanyl elective group) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with opioid analgesic combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic with opioid analgesic combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl) Anesthesia and Pain Management Small molecule

Target snapshot

Bupivacaine-fentanyl elective group (Bupivacaine-fentanyl elective group) — Conrad Arnfinn Bjørshol. Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, while fentanyl is an opioid agonist that binds to mu opioid receptors to provide analgesia, together delivering regional anesthesia and analgesia for elective procedures.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine-fentanyl elective group TARGET	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Levobupivacaine and Fentanyl	Levobupivacaine and Fentanyl	Hamad Medical Corporation	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels; mu-opioid receptor
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
Bupivacaine and Fentanyl	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
Naropin 0.1% cum sufentanil	Naropin 0.1% cum sufentanil	Bent Gymoese Jorgensen	phase 3	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with opioid analgesic combination class)

1. Bent Gymoese Jorgensen · 1 drug in this class
2. Bnai Zion Medical Center · 1 drug in this class
3. Conrad Arnfinn Bjørshol · 1 drug in this class
4. Hamad Medical Corporation · 1 drug in this class
5. National Institute for Tuberculosis and Lung Diseases, Poland · 1 drug in this class